Amgen's D-mab posts positive in late-stage trial

Amgen got a badly needed boost with its announcement that its most promising experimental therapy, denosumab, significantly increased bone mineral density in a Phase III trial. The drug, delivered as a twice yearly injection, outperformed Fosamax in a study that was wrapped in January. This new study focused on the outcomes of 332 patients with post-menopausal osteoporosis.

"The effect of denosumab on wrist BMD [bone mineral density], reinforced by the BMD increases at the total body and hip regions, suggests denosumab has a positive effect on highly cortical sites," said Javier San Martin, global development lead for the denosumab osteoporosis program.

Data on another late-stage study evaluating denosumab's impact on fracture risk reduction in women with postmenopausal osteoporosis is due later this year.

- see Amgen's release on the trial
- check out the report in the Wall Street Journal

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.